Ginger and cancer: what preclinical studies say about curcumin and gingerol

Ginger, curcumin and cancer: scientific overview

Important Warning: The data presented are PRECLINICAL (in vitro and animal). Ginger and turmeric are NOT cancer treatments. Never replace conventional treatment. Always consult your oncologist.

What preclinical studies show

Curcumin and gingerol are among the most studied natural compounds in anticancer research, with more than 12,000 publications on PubMed.

Three documented mechanisms (in vitro)

Mechanism	Compound	Action	References
NF-κB inhibition	Curcumin + Gingerol	Blocks tumor cell survival	Aggarwal et al., 2004
Apoptosis induction	Curcumin	Activation of caspases 3/9	Ravindran et al., 2009
Angiogenesis inhibition	Curcumin	↓ VEGF (tumor vascularization)	Arbiser et al., 1998

Why NF-κB is an anticancer target

NF-κB is constitutively activated in many cancers (colorectal, breast, prostate, pancreas). Its inhibition is an active research strategy in oncology. Curcumin and gingerol inhibit NF-κB through complementary pathways (IKK-β and IκBα).

Important Limitations

• In vitro ≠ in vivo — results on cells do not always translate to humans
• Bioavailability — in vitro concentrations are often unrealistic orally
• Clinical trials — Phase II in progress, preliminary results
• Complementary only — never as a replacement for standard treatment

The sugar factor in oncology

NF-κB is activated in many cancers. Sugar activates NF-κB (Mauro, 2011). Reducing sugar is consistent with oncology research — even if a shot alone is not a treatment.

INTI — organic ginger + turmeric + black pepper, 1.19g sugar/100ml. Complementary, not curative. Consult your doctor.